Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma

Cancer

Volumn 97, Issue 4, 2003, Pages 1015-1024

  Kunkel, Martin ^a   Reichert, Torsten E ^a   Benz, Peter ^a   Lehr, Hans Anton ^a   Jeong, Jong Hyeon ^b   Wieand, Samuel ^b   Bartenstein, Peter ^a   Wagner, Wilfried ^a   Whiteside, Theresa L ^c,d  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

18F 2 fluoro 2 deoxy D glucose; Glucose transport; Glut 1 expression; Oral carcinoma; Positron emission tomography; Prognosis

Indexed keywords

GLUCOSE TRANSPORTER 1;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; GENE OVEREXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; LABELING INDEX; MAJOR CLINICAL STUDY; MOUTH CARCINOMA; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TRANSPORT KINETICS;

CARCINOMA, SQUAMOUS CELL; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MALE; MONOSACCHARIDE TRANSPORT PROTEINS; MOUTH NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037441913     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11159     Document Type: Article

References (33)

1. Warburg O. Über den Stoffwechsel der Carcinom-Zelle. Klinsche Wochenschrift. 1925;4:534-536.
2. Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990;170:223-230.
3. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 1996;56:1164-1167.
4. Mellanen P, Minn H, Grenman R, Harkonen P. Expression of glucose transporters in head-and-neck tumors. Int J Cancer. 1994;56:622-629.
5. Reisser C, Eichhorn K, Herold Mende C, Born AI, Bannasch P. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer. 1999;80:194-198.
6. Pao SS, Paulsen IT, Saier MH. Major facilitator superfamily. Microbiol Mol Biol Rev. 1998;62:1-34.
7. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492-1495.
8. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut-1 mRNA by hypoxia-inducible factor-1. J Biol Chem. 2001;276:9519-9525.
9. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I non small cell lung carcinoma is associated with poor survival. Cancer. 1997;80:1046-1051.
10. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83:34-40.
11. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma. Cancer. 2001;92:634-641.
12. Baer S, Casaubon L, Schwartz MR, Macrogliese A, Younes M. Glut-3 expression in biopsy specimens of laryngeal carcinoma is associated with poor survival. Laryngosope. 2002;112:393-396.
13. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32:623-648.
14. Ahuya V, Coleman RE, Herndon J, Patz EF. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non small cell lung carcinoma. Cancer. 1998;83:918-924.
15. Dhital K, Saunders CA, Seed PT, O'Doherty MJ, Dussek J. [(18)F] fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg. 2000;18:425-428.
16. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer. 1998;82:2227-2234.
17. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201-3206.
18. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907-1911.
19. Rege S, Safa AA, Chaiken L, Hoh C, Juillard G, Withers HR. Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas. Am J Clin Oncol. 2000;23:164-169.
20. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86:512-516.
21. Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398-1404.
22. Wittekind C, Wagner G. TNM-Klassifikation maligner Tumoren, 5th ed. Berlin: Springer, 1997.
23. Battifora H. Assessment of antigen damage in immunohistochemistry. The vimentin internal control. Am J Clin Pathol. 1991;96:669-671.
24. Mohr C, Bohndorf W, Gremmel H, et al. Preoperative radiochemotherapy and radical surgery of advanced head and neck cancers - results of a prospective, multicenter DOSAK study. Recent Results Cancer Res. 1994;134:155-163.
25. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993;189:847-850.
26. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A. 1972;135:185-206.
27. Airley R, Loncaster J, Davidson S, et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 2001;7:928-934.
28. Chang S, Lee S, Lee C, Kim JI, Kim Y. Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology. 2000;55:448-452.
29. Juarez D, Lechago LV, Somoano J, Younes M. Glut1 expression in transitional cell carcinoma of the urinary bladder correlates with aggressive biologic behavior [abstract]. Lab Invest. 1997;74:75A.
30. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent of low expression of the ζ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998;58:5344-5347.
31. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and ζ-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer. 2001;91:2136-2147.
32. Shim H, Chun YS, Lewis BC, Dang CV. A unique glucose dependent apoptotic pathway induced by e-myc. Proc Natl Acad Sci USA. 1998;95:1511-1516.
33. Haberkorn U, Bellemann ME, Brix G, et al. Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med. 2001;28:418-425.